GlassScriptPhysician profile
Jamie L Walter
NPI 1295492338
$860.19
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $716 · 2024: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $860.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $195.94 | 2023 | Spravato |
| Idorsia Pharmaceuticals US INC | $157.24 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.54 | 2023-2024 | Caplyta |
| Axsome Therapeutics, INC. | $101.52 | 2023 | Auvelity |
| Corium, LLC | $73.14 | 2023-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $62.92 | 2023-2024 | Rexulti |
| Abbvie INC. | $42.09 | 2023-2024 | |
| Noven Therapeutics, LLC | $32.37 | 2023 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $16.98 | 2023 | Jornay Pm |
| Lundbeck LLC | $16.06 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $15.56 | 2023 | Austedo Xr |
| Neurocrine Biosciences, INC. | $14.86 | 2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $13.97 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Walter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.